Toxicity Linked to Longer Survival in Patients With NSCLC Toxicity Linked to Longer Survival in Patients With NSCLC
A new cohort study shows that some immune-related adverse events are linked to longer survival in patients with NSCLC treated with immunotherapy.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 30, 2024 Category: Consumer Health News Tags: Hematology-Oncology Source Type: news
Injected Opdivo for Kidney Cancer Works Equally Well as IV Form: Study
TUESDAY, Jan. 30, 2024 -- Opdivo, one of the new generation of immunotherapy cancer treatments, appears to help kidney cancer patients equally well when given as a quick injection versus the current method of intravenous delivery, a new study... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - January 30, 2024 Category: General Medicine Source Type: news
Subcutaneous Nivolumab as Effective as IV for Renal Cell Carcinoma -- With Much Faster Treatment Time
Subcutaneous injection of the immunotherapy nivolumab (brand name Opdivo) is noninferior to intravenous delivery and dramatically reduces treatment time in patients with renal cell carcinoma, as reported by Dr. Saby George of Roswell Park Comprehensive Cancer Center today at the 2024... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - January 29, 2024 Category: Pharmaceuticals Tags: TRI Source Type: news
Hope in the fight against cancer as scientists discover a 'vital weak spot' for tumours
Some cancers are treated with immunotherapy - drugs that harness the body's natural defences to attack cancer cells - but with varying degrees of success. (Source: the Mail online | Health)
Source: the Mail online | Health - January 29, 2024 Category: Consumer Health News Source Type: news
Live tumor imaging company Elephas garners $55M
The company ' s diagnostics platform helps predict how patients will respond to immunotherapy. (Source: mobihealthnews)
Source: mobihealthnews - January 24, 2024 Category: Information Technology Source Type: news
Immunotherapy for Pancreatic Cancer: Peptidic Targeting of a Tumor-Specific Glycan, Upcoming Webinar Hosted by Xtalks
In this free webinar, gain insights into an intracellular delivery platform to internalize biotherapeutics to specific target cells. Attendees will learn about molecular guidance systems (MGSs) that can be identified for virtually any cell type. The featured speaker will discuss a novel... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - January 24, 2024 Category: Pharmaceuticals Source Type: news
FDA Issues Warning of Cancer Risk Tied to CAR-T Therapies
The agency has reviewed reports of cancer patients whose treatments resulted in the development of secondary blood cancers. Several companies will be required to carry the new warning. (Source: NYT Health)
Source: NYT Health - January 23, 2024 Category: Consumer Health News Authors: Christina Jewett Tags: Cancer Immunotherapy Blood Deaths (Fatalities) Genetic Engineering Labeling and Labels (Product) Food and Drug Administration Bristol Myers Squibb Company Janssen Pharmaceutica Juno Therapeutics Inc Kite Pharma Inc Novartis AG Source Type: news
Immunotherapy Combo Wins Big on PFS in First-Line Mets CRC Immunotherapy Combo Wins Big on PFS in First-Line Mets CRC
First-line nivolumab plus ipilimumab led to significantly better 2-year PFS in metastatic CRC than chemotherapy as well as pembrolizumab monotherapy.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 23, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Big PFS Improvement in Highly Mutated CRC With Dual Immunotherapy
(MedPage Today) -- SAN FRANCISCO -- Frontline dual immunotherapy significantly improved progression-free survival (PFS) versus chemotherapy in microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) metastatic colorectal cancer... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - January 22, 2024 Category: Gastroenterology Source Type: news
Adding Immunotherapy, Anti-TIGIT in First Line Boosts OS in Esophageal Cancer
(MedPage Today) -- SAN FRANCISCO -- Adding the novel anti-TIGIT monoclonal antibody tiragolumab plus atezolizumab (Tecentriq) to standard first-line chemotherapy significantly improved survival for patients with advanced esophageal squamous cell... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - January 20, 2024 Category: Gastroenterology Source Type: news
Long-Term Data Affirm First-Line Immunotherapy for Advanced Esophageal Cancer
(MedPage Today) -- SAN FRANCISCO -- A chemoimmunotherapy combination significantly improved long-term survival in advanced esophageal cancer as compared with chemotherapy, follow-up data from a randomized trial showed.
Pembrolizumab (Keytruda... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - January 19, 2024 Category: Gastroenterology Source Type: news
Immunotherapy Initiated Near Death in Metastatic Cancer Immunotherapy Initiated Near Death in Metastatic Cancer
Patients with metastatic cancer are increasingly starting immunotherapy within a month prior to death, new data show.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 19, 2024 Category: Consumer Health News Tags: Hematology-Oncology Source Type: news
European Commission approves Roche & #039;s Tecentriq SC, the EU & #039;s first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the European Commission has granted marketing authorisation for Tecentriq® SC (atezolizumab), the European Union (EU)'s first PD-(L)1 cancer immunotherapy for subcutaneous (under the skin) injection. Subcutaneous (SC) injection offers the potential for a faster, more convenient alternative to intravenous (IV) infusion and is preferred by cancer patients, nurses and physicians (Source: World Pharma News)
Source: World Pharma News - January 17, 2024 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news
